 | This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (January 2024) |
 | |
| Clinical data | |
|---|---|
| Trade names | Joycle |
| Other names | Diclofenac etalhyaluronate sodium (JAN); SI-613 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| PubChem SID | |
| UNII | |
| KEGG | |
Diclofenac etalhyaluronate (INN, USAN; trade name Joycle) is an anti-inflammatory and joint function improving drug. In Japan it is approved for use in the treatment of knee osteoarthritis.
Chemically, diclofenac etalhyaluronate consists of the drug diclofenac, a nonsteroidal antiinflammatory drug, covalently linked to hyaluronic acid. In the body, diclofenac is slowly cleaved and released, allowing diclofenac etalhyaluronate to function as a sustained-release form of diclofenac.
References
- "Diclofenac etalhyaluronate - Seikagku Corporation". Adis Insight. Springer Nature Switzerland AG.
- "New Drug Approvals in Japan". KEGG.
- Kisukeda T, Onaya J, Yoshioka K (2019). "Effect of diclofenac etalhyaluronate (SI-613) on the production of high molecular weight sodium hyaluronate in human synoviocytes". BMC Musculoskelet Disord. 20 (201): 201. doi:10.1186/s12891-019-2586-0. PMC 6511136. PMID 31077160.
- Nishida Y, Kano K, Nobuoka Y, Seo T (September 2021). "Efficacy and Safety of Diclofenac-Hyaluronate Conjugate (Diclofenac Etalhyaluronate) for Knee Osteoarthritis: A Randomized Phase III Trial in Japan". Arthritis & Rheumatology. 73 (9). Hoboken, N.J.: 1646–1655. doi:10.1002/art.41725. PMC 8456865. PMID 33749997.
 | This drug article relating to the musculoskeletal system is a stub. You can help Misplaced Pages by expanding it. |